Hormone replacement therapy: Effect of progestin dose and time since menopause on endometrial bleeding

Obstetrics and Gynecology

Volumn 96, Issue 6, 2000, Pages 899-905

  Archer, David F ^a,b   Pickar, James H ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; UTERUS BLEEDING;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; UTERINE HEMORRHAGE;

EID: 0033732301     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)01036-X     Document Type: Article

References (35)

1. Prevention and treatment of osteoporosis: Does the future belong to hormone replacement therapy?
2. Hormone therapy to prevent disease and prolong life in postmenopausal women
3. Hormonal treatment of postmenopausal women
4. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
5. The Postmenopausal Estrogen/Progestin Interventions study: Primary outcomes in adherent women
6. Estrogen and cognitive functioning in women
7. Estrogen effects on cognition in menopausal women
8. Estrogen replacement therapy and risk of Alzheimer disease
9. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
10. Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States
11. Hormone replacement therapy and risk of colon and rectal cancer
12. Postmenopausal hormone use and risk for colorectal cancer
13. Postmenopausal hormone therapy and mortality
14. Patient-specific decisions about hormone replacement therapy in postmenopausal women
15. Decreased mortality in users of estrogen replacement therapy
16. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
17. Compliance difficulties with progestin-supplemented estrogen replacement therapy
18. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
19. Women's concerns with hormone replacement therapy - Compliance issues
20. Compliance with hormone replacement therapy: Where we stand today
21. Compliance with hormone replacement therapy in postmenopausal women. A comparative study
22. Enhancing patient compliance with hormone replacement therapy at menopause
23. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. The Menopause Study Group
24. Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
25. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
26. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
27. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group
28. Amenorrhea frequency with continuous combined hormone replacement therapy: A retrospective analysis. Menopause Study Group
29. Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: Are there advantages?
30. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study
31. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Endometrial Cancer Collaborative Group
32. Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995
33. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
34. Estrogen-progestin replacement therapy and endometrial cancer
35. Risk of endometrial cancer following estrogen replacement with and without progestins